Tous Actualités
Suivre
Abonner Helsinn Healthcare SA

Helsinn Healthcare SA

Helsinn and Vifor Pharma sign new contract for Gelclair in Switzerland

Lugano (ots)

New therapeutic option for the management of
painful symptoms of oral mucositis in the oncology setting soon 
available for Swiss patients
Helsinn, the pharmaceutical group based in Lugano, and Vifor 
Pharma, are pleased to announce that a Distribution & Licensing 
Agreement for Helsinn's product Gelclair in Switzerland has been 
signed recently. The product launch on the domestic market is 
foreseen to take place during the fourth quarter 2010.
Gelclair is a viscous, concentrated, bioadherent oral gel with a 
mechanical protective action, which relieves pain by adhering to the 
mucosal surface of the mouth. By this action, it sooths mucositis and
stomatitis oral lesions caused by radio and chemotherapy.
Gelclair represents an ideal complement in Vifor Pharma's 
supportive care and oncology portfolio and this new bond further 
reinforces the strong business relationship that Vifor Pharma and 
Helsinn have built through the successful agreements in force for 
nimesulide and palonosetron. "Helsinn is confident that Vifor 
Pharma's expertise and commitment will ensure a high recognition of 
the important role that Gelclair can play in the management of oral 
mucositis in cancer patients" said Riccardo Braglia, CEO of the 
Helsinn Group.
Dr. Josef Troxler, General Manager Vifor Pharma Rx Switzerland, 
adds, "Together with palonosetron and our i.v. iron products, 
Gelclair will strengthen Vifor Pharma's position in supportive care 
and help cancer patients in alleviating their symptoms and adhering 
to the treatment".
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with 
headquarters in Lugano, Switzerland and subsidiaries in Ireland and 
USA. Helsinn's business model is focused on the licensing of 
pharmaceuticals and medical devices in therapeutic niche areas. The 
Group in-licenses early to late stage new chemical entities, 
completes their development from the performance of pre- 
clinical/clinical studies and Chemistry, Manufacturing and Control 
(CMC) development, to the filing for and attainment of their market 
approval worldwide.
Helsinn's products are sold directly, through the Group 
subsidiaries, or out-licensed to its network of local marketing and 
commercial partners, selected for their deep in-market knowledge and 
know-how, and assisted and supported with a full range of product and
scientific management services, including commercial, regulatory, 
financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage 
forms are manufactured at Helsinn's cGMP facilities in Switzerland 
and Ireland, and supplied worldwide to its customers. Helsinn is the 
worldwide licensor of palonosetron, a second generation 5-HT3 
receptor antagonist, for the prevention of chemotherapy-induced 
nausea and vomiting (CINV) in patients with cancer and of 
post-operative nausea and vomiting (PONV), and of the original 
nimesulide, a non-steroidal anti-inflammatory drug (NSAID) 
distributed in more than 50 countries worldwide.
Helsinn, with a workforce of around 450 employees in Switzerland, 
Ireland and USA, reported a 2009 turnover of over CHF 305 million 
(about EUR 200 million), covering 85 countries worldwide, with over 
20% of this turnover invested in R&D.
For more information about Helsinn Group, please visit the 
website: www.helsinn.com
For more information about Vifor Pharma, please visit the website:
www.viforpharma.com

Contact:

Paolo Ferrari
Head of International Marketing Helsinn Healthcare SA
Tel.: +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

Vifor Pharma
Harriet Sihn
Flughofstrasse 61
P.O. Box
CH-8152 Glattbrugg
Tel.: +41/58/851'80'00
Fax: +41/58/851'80'01
Internet: www.viforpharma.com

Plus de actualités: Helsinn Healthcare SA
Plus de actualités: Helsinn Healthcare SA
  • 22.04.2010 – 10:39

    The 5-HT3 Receptor Antagonist Aloxi® launched in Japan

    Lugano, Switzerland / Tokyo, Japan (ots) - Helsinn Healthcare SA, Switzerland, and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce the launch of Aloxi® injection today. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement between Taiho and Helsinn of January 2004, and its marketing ...

  • 20.01.2010 – 10:30

    Oncology: Palonosetron approved in Japan, second pharmaceutical market wordwide

    Lugano/Tokyo, Japan (ots) - The second generation 5-HT3 receptor antagonist palonosetron available in more than 50 countries worldwide, including US, EU and Japan Today, Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, gained marketing approval in Japan for this drug indicated for the ...

  • 11.01.2010 – 12:00

    The Helsinn Group Implements New Organizational Structure

    Lugano (ots) - Giorgio Calderari promoted to Group General Manager, responsible for Corporate, Business Development, R&D, Technical Affairs, Commercial, and Manufacturing functions Riccardo Braglia has been confirmed as CEO of the Helsinn Group. His role will focus on the Group's fundamental strategic tasks, including internal and external growth, and new market opening. Riccardo Braglia will also directly ...